NYBC Ventures logo
VC

NYBC Ventures

Netherlandsnybcventures.org

NYBC Ventures is a venture capital firm based in the Netherlands, investing in Healthcare & Life Sciences, Software & Developer Tools and Finance & Blockchain, 15 tracked investments.

15
Investments Tracked

About NYBC Ventures

NYBC Ventures is a venture capital firm based in the Netherlands. Brouky tracks 15 investments associated with the firm.

NYBC Ventures invests across Healthcare & Life Sciences, Software & Developer Tools, Finance & Blockchain and Biotechnology. Coverage extends to 8 sectors in total. Participation spans Pre-Seed, Series B and Series C+ rounds.

The firm invests in early to mid stage innovations in blood and cellular therapies and related technologies, focusing on therapeutics, devices, and other breakthrough solutions in hematology, transfusion medicine, cell therapy, and infectious disease.

Investment Focus

Stage Focus
pre-seedseries-bseries-c-plus
Sectors
Healthcare & Life SciencesSoftware & Developer ToolsFinance & Blockchainbiotechnologymedical-deviceAutomationHealthcare Techimmunotherapy

Investment Thesis

The firm invests in early to mid stage innovations in blood and cellular therapies and related technologies, focusing on therapeutics, devices, and other breakthrough solutions in hematology, transfusion medicine, cell therapy, and infectious disease.

NYBC Ventures Portfolio Companies

12 tracked holdings.

Portfolio outcomes
15 active

Team

Christopher D. HillyerGeneral Partner Manager

President and CEO, New York Blood Center Enterprises (NYBCe); General Partner, NYBC Ventures; Distinguished Investigator, Lindsley F. Kimball Research Institute; and Professor, Department of Medicine, Weill Cornell College of Medicine.

Jay MohrGeneral Partner Manager

Executive Vice President and Chief Business Officer, provides business development leadership and directs NYBCe’s cell manufacturing business unit, Comprehensive Cell Solutions®, as well as the Enterprise’s specialty pharmacy.

Meg WoodManaging Director

Leverages her expertise in venture capital and strategic investments to identify and support innovative companies, driving the firm’s investment strategy.

Kuan YuSr Analyst

Since joining NYBC Ventures in 2024, Kuan has played an important role, identifying and assessing companies within NYBCV’s core focus areas.

John RosenthalChair

Executive Vice President (EVP) and Chief Investment Officer of Brighthouse Financial, responsible for the overall management of the company’s investment portfolio.

Jung ChoiManager

Biotech executive, Board member, and advocate for patients, was chief business and strategy officer for Global Blood Therapeutics (GBT), a leader in sickle cell disease.

David KabakoffAnalyst

Organic and biochemist with over 30 years of experience in leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields.

Cristina CsimmaMember

Biopharmaceutical leader with decades of experience in global drug development, new company formation and value creation in biotechnology, large pharma and venture capital.

CHRISTOPHER D. HILLYER, MDGENERAL PARTNER
MEG WOOD, MPHMANAGING DIRECTOR
JOHN MARAGANRORESTRATEGIC ADVISOR

Explore NYBC Ventures's full profile on Brouky

Portfolio companies, co-investors, AI match scores, and deal flow signals.

Other Investors in Netherlands

Other Investors in Healthcare & Life Sciences / Software & Developer Tools